Malaysia PEGylated Proteins market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The market for PEGylated Proteins is growing rapidly as a result of the growing incidence and prevalence of degenerative & chronic diseases like cancer, kidney diseases, and rheumatoid arthritis. Thermo Fisher Scientific Inc., Merck KGaA, NOF Corporation, Jenkem Technology, etc., are some of the key players in this market.
Malaysia PEGylated Proteins Market is valued at around $19.1 Mn in 2022 and is projected to reach $30.4 Mn by 2030, exhibiting a CAGR of 5.99% during the forecast period 2023-2030.
The process of covalently joining polyethylene glycol (PEG) chains to proteins or peptides is known as pegylation. To improve the stability, pharmacokinetics, immunogenicity, and circulation time of proteins in the body, this modification technique has been widely employed to improve the characteristics and therapeutic potential of proteins. PEGylation alters the electrostatic binding, confirmation, and hydrophobicity of the molecule, increasing the molecule's stability and solubility while reducing immunogenicity. Numerous PEGylated Protein medicines have been approved by regulators and successfully commercialized. PEGylated asparaginase (Oncaspar) is used to treat acute lymphoblastic leukemia, PEGylated filgrastim (Neulasta) is used to support cancer patients undergoing chemotherapy, and PEGylated interferons (such as Pegasys and PegIntron) are used to treat hepatitis C. Thermo Fisher Scientific Inc., Merck KGaA, NOF Corporation, Jenkem Technology, celares GmbH, Creative PEGWorks, Quanta BioDesign, Ltd., Biomatrik Inc., Layson Bio Inc. are the key players in this market.
Market Growth Drivers
Rising prevalence of lifestyle diseases and rising prevalence of degenerative & chronic diseases like cancer, kidney diseases, and rheumatoid arthritis, growing demand for protein-based therapies as a wide range of therapies are protein-based including growth factors, enzymes, antibodies, and cytokines, increased in research activities for the development of novel therapeutics, expanding therapeutic applications of PEGylated proteins in areas such as oncology, autoimmune diseases, hematology, and metabolic disorders.
Improved Drug Delivery Systems: PEGylation has been used to develop long-acting formulations and drug delivery systems, enabling less frequent dosing and improved patient convenience. All these factors act as market growth drivers.
Market Restraints
Failures in PEGylated Proteins drug development and huge costs associated with PEGylated Proteins drugs development. This factor acts as a market growth restraint.
Key Players
In July 2022, Doxorubicin hydrochloride (Celdoxome pegylated liposomal) was recommended for approval by the European Medicines Agency (EMA) for the treatment of metastatic breast cancer, advanced ovarian cancer, progressing multiple myeloma, and AIDS-related Kaposi's sarcoma.
In February 2022, Exelead a biopharmaceutical company that specializes in PEGylated pharmaceuticals and difficult injectable formulations, including drug delivery technology based on lipid nanoparticles (LNPs) was acquired by Merck.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Product
By Protein Type
By Application
By End-Users
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.